Associate Director, Marketing
Lexeo Therapeutics
This listing was originally posted on Lexeo Therapeutics's careers page. Formulate is an equal opportunity job aggregator and is not involved in the hiring process. Where salary information is estimated, it is derived from BLS industry benchmarks and may differ from actual compensation.
Upgrade to Pro to access the AI-generated 'Read before applying' briefing and other premium pharma intelligence.
Upgrade to Pro — $25/moRole Summary
Lexeo’s Commercial team is building the strategy, insights, brand and infrastructure required to bring LX2006 to patients – marking Lexeo’s transition from a clinical-stage to a commercial company.
We are seeking an Associate Director, Marketing to play a central role in preparing for the launch of LX2006, Lexeo’s first commercial product, anticipated in the US in 2028 and globally thereafter. Reporting to the Senior Director, Marketing, this individual will serve as the LX2006 brand lead, owning critical launch workstreams end to end – from customer insights and competitive intelligence to market development, campaigns, customer targeting and launch readiness – and working closely with cross-functional partners in Market Access/HEOR, Medical Affairs, Patient Affairs, Clinical Development, Regulatory, Legal, CMC, and Business Development (ad hoc) as part of Lexeo’s Launch Readiness Team.
The role will also support early commercial planning for LX2020, Lexeo’s gene therapy candidate for PKP2-associated arrhythmogenic cardiomyopathy.
This is a highly visible, hands-on opportunity to build a launch from the ground up and help shape the commercial foundation of a growing clinical stage company.
We welcome applications from candidates located across the Northeast and Mid-Atlantic.
About LEXEO
Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.
Our work culture is a hybrid model with 2 days in the New York City office and 3 days working from home.
LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.
Explore related positions you might be interested in
We'll notify you when matching roles are posted.
Interviewed at Lexeo Therapeutics?
Help others prepare — share your experience anonymously.
BIOTECHNOLOGY
Gene Therapy
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo